National survey on the experiences of people with celiac disease in Spain. The CELIAC-SPAIN project
Introduction: coeliac disease (CD) is well known, but not so its impact on the patient’s life. Objective: to determine the impact of CD in the life of celiac patients on different aspects such as diagnosis, follow-up and treatment. Material and methods: associates of FACE participated in an auto-adm...
| Autores: | , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universidad de Sevilla (US) |
| Repositorio: | idUS. Depósito de Investigación de la Universidad de Sevilla |
| OAI Identifier: | oai:idus.us.es:11441/158017 |
| Acceso en línea: | https://hdl.handle.net/11441/158017 https://doi.org/10.17235/reed.2020.6929/2020 |
| Access Level: | acceso abierto |
| Palabra clave: | Celiac disease Impact Epidemiology Relatives Survey Gluten-free diet |
| Sumario: | Introduction: coeliac disease (CD) is well known, but not so its impact on the patient’s life. Objective: to determine the impact of CD in the life of celiac patients on different aspects such as diagnosis, follow-up and treatment. Material and methods: associates of FACE participated in an auto-administered, telematic survey conducted between May and July, 2019. Three participant profiles have been defined: adults diagnosed in adulthood, adults diagnosed in childhood and parents/guardians of celiac children. Results: 540 surveys (343 adult celiacs, 58 celiacs from children and 139 parents/guardians) from all autonomous communities have been included. In the diagnostic process highlights the diagnostic delay (up to 2 years) and the lim itations to screening of family members. After diagnosis, about 20 % of adults do not refer to follow any control. Having a CD generates different reactions, but concern and quality of life limitation are very common. As for the glu ten-free diet, 90 % of patients referred good adherence to treatment, which is accompanied by improved symptoms and weight gain. Diet tracking limits patients’ daily lives. Gluten-free manufactured products are considered expen sive, with unclear and unappealing labeling. Conclusions: the results of the “CELIAC-SPAIN” project show that there are still many aspects to be improved in CD, both diagnosis and follow-up and in facilitating access to gluten-free products. |
|---|